AKT1 and small cell lung carcinoma: An emerging obstacle in targeted therapeutics that hinders durable responses is acquired on-target resistance due to for example: 1) mutations in the driver oncogene, such as EGFR T790M (3), or EML4-ALK C1156Y or L1196M (4) thus causing resistance to first-line treatments, 2) activation of an alternative signaling pathway, such as PI3K/AKT (Phosphoinositide 3-kinase/Akt serine/threonine protein kinase also known as protein kinase B) for cisplatin resistance (5), and 3) histological transformation into small cell lung cancer (6), or epithelial-mesenchymal transition (7), among others.